Evaluating the health and health economic impact of the COVID-19 pandemic on delayed cancer care in Belgium: A Markov model study protocol.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 18 11 2022
accepted: 28 06 2023
medline: 1 11 2023
pubmed: 30 10 2023
entrez: 30 10 2023
Statut: epublish

Résumé

Cancer causes a substantial burden to our society, both from a health and an economic perspective. To improve cancer patient outcomes and lower society expenses, early diagnosis and timely treatment are essential. The recent COVID-19 crisis has disrupted the care trajectory of cancer patients, which may affect their prognosis in a potentially negative way. The purpose of this paper is to present a flexible decision-analytic Markov model methodology allowing the evaluation of the impact of delayed cancer care caused by the COVID-19 pandemic in Belgium which can be used by researchers to respond to diverse research questions in a variety of disruptive events, contexts and settings. A decision-analytic Markov model was developed for 4 selected cancer types (i.e. breast, colorectal, lung, and head and neck), comparing the estimated costs and quality-adjusted life year losses between the pre-COVID-19 situation and the COVID-19 pandemic in Belgium. Input parameters were derived from published studies (transition probabilities, utilities and indirect costs) and administrative databases (epidemiological data and direct medical costs). One-way and probabilistic sensitivity analyses are proposed to consider uncertainty in the input parameters and to assess the robustness of the model's results. Scenario analyses are suggested to evaluate methodological and structural assumptions. The results that such decision-analytic Markov model can provide are of interest to decision makers because they help them to effectively allocate resources to improve the health outcomes of cancer patients and to reduce the costs of care for both patients and healthcare systems. Our study provides insights into methodological aspects of conducting a health economic evaluation of cancer care and COVID-19 including insights on cancer type selection, the elaboration of a Markov model, data inputs and analysis.

Identifiants

pubmed: 37903130
doi: 10.1371/journal.pone.0288777
pii: PONE-D-22-31778
pmc: PMC10615261
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0288777

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright: © 2023 Khan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

JAMA Dermatol. 2019 Jun 1;155(6):688-693
pubmed: 31042258
Anticancer Res. 2019 Oct;39(10):5721-5724
pubmed: 31570473
J Surg Res. 2019 Mar;235:551-559
pubmed: 30691842
Pharmacoeconomics. 2018 Jun;36(6):675-697
pubmed: 29470821
JAMA Netw Open. 2020 Dec 1;3(12):e2030072
pubmed: 33315115
Health Serv Res. 2018 Dec;53 Suppl 3:5331-5351
pubmed: 30246404
Eur J Cancer. 2021 Nov;157:308-347
pubmed: 34560371
Transl Behav Med. 2018 May 23;8(3):503-508
pubmed: 29800404
Commun Med (Lond). 2022 Apr 7;2:31
pubmed: 35603309
ESMO Open. 2021 Aug;6(4):100197
pubmed: 34474811
Front Public Health. 2020 Oct 30;8:569500
pubmed: 33194969
Eur J Cancer. 2021 Jul;152:233-242
pubmed: 34049776
Med Decis Making. 1993 Oct-Dec;13(4):322-38
pubmed: 8246705
JCO Glob Oncol. 2021 Feb;7:311-323
pubmed: 33617304
Nat Rev Clin Oncol. 2020 May;17(5):268-270
pubmed: 32242095
Lancet Oncol. 2015 Sep;16(10):1153-86
pubmed: 26419354
Lancet Oncol. 2021 Nov;22(11):1507-1517
pubmed: 34624250
Eur J Oncol Nurs. 2021 Feb;50:101880
pubmed: 33333451
J Natl Cancer Inst. 2022 Mar 8;114(3):391-399
pubmed: 34747484
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Value Health. 2022 Jan;25(1):10-31
pubmed: 35031088
Lancet Oncol. 2021 Mar;22(3):309-320
pubmed: 33493433
Med Decis Making. 2012 Sep-Oct;32(5):722-32
pubmed: 22990087
Qual Life Res. 2019 Dec;28(12):3153-3161
pubmed: 31531840
Appl Health Econ Health Policy. 2018 Dec;16(6):765-778
pubmed: 30094591
BMC Endocr Disord. 2020 Mar 12;20(Suppl 1):14
pubmed: 32164685
Am J Epidemiol. 2011 Apr 1;173(7):731-8
pubmed: 21415029
Value Health. 2003 Jan-Feb;6(1):9-17
pubmed: 12535234
Am J Epidemiol. 1999 Jan 15;149(2):195-7
pubmed: 9921965
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
Eur J Cancer. 2020 Apr;129:41-49
pubmed: 32120274
Cancers (Basel). 2023 Mar 14;15(6):
pubmed: 36980640
Value Health. 2012 Sep-Oct;15(6):812-20
pubmed: 22999130
Pharmacoeconomics. 2015 Dec;33(12):1255-68
pubmed: 26105525
Clin Breast Cancer. 2023 Apr;23(3):265-271
pubmed: 36717319
Lancet. 2016 Nov 26;388(10060):2576-2577
pubmed: 27894651
Dis Colon Rectum. 2018 Sep;61(9):1016-1025
pubmed: 30086050
Front Public Health. 2021 Jun 29;9:675523
pubmed: 34268287

Auteurs

Yasmine Khan (Y)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Interface Demography, Department of Sociology, Vrije Universiteit Brussel, Brussels, Belgium.

Nick Verhaeghe (N)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Research Institute for Work and Society, KU Leuven, Leuven, Belgium.

Robby De Pauw (R)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.

Brecht Devleesschauwer (B)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Department of Translational Physiology, Infectiology and Public Health, Ghent University, Merelbeke, Belgium.

Sylvie Gadeyne (S)

Interface Demography, Department of Sociology, Vrije Universiteit Brussel, Brussels, Belgium.

Vanessa Gorasso (V)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Yolande Lievens (Y)

Radiation Oncology Department, Ghent University Hospital and Ghent University, Ghent, Belgium.

Niko Speybroek (N)

Research Institute of Health and Society, University of Louvain, Brussels, Belgium.

Nancy Vandamme (N)

Research Department, Belgian Cancer Registry, Brussels, Belgium.

Miet Vandemaele (M)

Radiation Oncology Department, Ghent University Hospital and Ghent University, Ghent, Belgium.

Laura Van den Borre (L)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Interface Demography, Department of Sociology, Vrije Universiteit Brussel, Brussels, Belgium.

Sophie Vandepitte (S)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.

Katrien Vanthomme (K)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Interface Demography, Department of Sociology, Vrije Universiteit Brussel, Brussels, Belgium.

Freija Verdoodt (F)

Research Department, Belgian Cancer Registry, Brussels, Belgium.

Delphine De Smedt (D)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH